Immune damage may explain ineffectiveness of high-dose radiation against lung cancer

When it comes to using radiation against lung cancer, preliminary clinical studies were pretty clear: More is better. So why did a large phase 3 clinical trial find exactly the opposite—that stage III non-small cell lung cancer patients treated with higher doses of radiation actually had shorter overall survival than patients treated with lower-dose radiation?

* This article was originally published here